The VISA-P originally developed to assess patellar tendinopathy severity,is increasingly being applied to patellofemoral pain(PFP)assessment.This editorial examines the expanding role of VISA-P within the context of e...The VISA-P originally developed to assess patellar tendinopathy severity,is increasingly being applied to patellofemoral pain(PFP)assessment.This editorial examines the expanding role of VISA-P within the context of existing patientreported outcome measures(PROMs)for PFP,such as the Kujala Anterior Knee Pain Scale and the Knee injury and Osteoarthritis Outcome Score for Patellofemoral Pain and Osteoarthritis.While VISA-P offers advantages in brevity,readability,and temporal stability,its original design targeting athletic populations with patellar tendinopathy limits its specificity and comparability when applied broadly to heterogeneous PFP populations.Moreover,VISA-P currently lacks validated diagnostic thresholds to guide clinical decision-making.Although the recent validation of VISA-P in Spanish-speaking populations enhances accessibility,caution is advised in its widespread adoption without clear delineation of its role relative to other PROMs.The editorial argues for careful contextual use of VISA-P,emphasizing the need for tools that balance specificity,efficiency,and universality to capture the complex spectrum of PFP across diverse populations.展开更多
文摘The VISA-P originally developed to assess patellar tendinopathy severity,is increasingly being applied to patellofemoral pain(PFP)assessment.This editorial examines the expanding role of VISA-P within the context of existing patientreported outcome measures(PROMs)for PFP,such as the Kujala Anterior Knee Pain Scale and the Knee injury and Osteoarthritis Outcome Score for Patellofemoral Pain and Osteoarthritis.While VISA-P offers advantages in brevity,readability,and temporal stability,its original design targeting athletic populations with patellar tendinopathy limits its specificity and comparability when applied broadly to heterogeneous PFP populations.Moreover,VISA-P currently lacks validated diagnostic thresholds to guide clinical decision-making.Although the recent validation of VISA-P in Spanish-speaking populations enhances accessibility,caution is advised in its widespread adoption without clear delineation of its role relative to other PROMs.The editorial argues for careful contextual use of VISA-P,emphasizing the need for tools that balance specificity,efficiency,and universality to capture the complex spectrum of PFP across diverse populations.
